Results 151 to 160 of about 19,015 (246)

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source

Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside

Journal of Sleep Research, EarlyView.
ABSTRACT Intermittent hypoxia (IH)‐mediated adipose tissue inflammation with M1 macrophage polarisation plays a key role in the pathogenesis of metabolic diseases in obstructive sleep apnoea (OSA). Effective treatment strategies are so far lacking.
Cliona O'Donnell, Ailbhe King, Guillaume Vial, Emily O'Neill, Shane Crilly, Jonathan D. Dodd, David J. Murphy, Elise Belaidi, Jean‐Louis Pepin, Claire Arnaud, Donal O'Shea, Silke Ryan   +11 more
wiley   +1 more source

Sight Unseen: Glucagon-Like Peptide-1 (GLP-1) Agonism Therapy and Nonarteritic Anterior Ischemic Optic Neuropathy. [PDF]

Cureus
Barnett MJ, Ibe F, Lam J.
europepmc   +1 more source

Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

Obesity Reviews, EarlyView.
ABSTRACT Anti‐obesity medications promote greater degrees of weight loss than lifestyle interventions alone. There is an important need to understand whether loss of skeletal muscle during pharmacologically induced weight loss is clinically significant due to its essential role in health and disease.
Arden McMath, Dympna Gallagher
wiley   +1 more source

Clinical Pharmacokinetics of Semaglutide: A Systematic Review

Drug Design, Development and Therapy
Xi-Ding Yang,1,2 Yong-Yu Yang1,3 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China; 2Phase I Clinical Trial Center, The Second Xiangya Hospital of Central South University ...
Yang XD, Yang YY
doaj  

FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity. [PDF]

JACC Adv
Do D, Murugiah K, Sawano M, Goodwin Cartwright BM, Rodriguez PJ, Gratzl S, Curtis LH, Jastreboff A, Lu Y, Stucky NL.   +9 more
europepmc   +1 more source

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source

Prolonged Semaglutide Treatment Reveals Stage-Dependent Changes to Feeding Behavior and Metabolic Adaptations in Male Mice. [PDF]

Diabetes
Shah H, Ayala JE.
europepmc   +1 more source

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence

Obesity Reviews, EarlyView.
ABSTRACT Next‐generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence‐based nutritional strategies to support safe and effective use of these agents remain limited.
Marie Spreckley, Cara F. Ruggiero, Adrian Brown   +2 more
wiley   +1 more source

Ketone therapy prevents semaglutide-induced loss of cardiac mass. [PDF]

Eur J Prev Cardiol
Schmidt MA, Abuetabh Y, Naganuma M, Vaka R, Zolondek MCP, Levasseur JL, Morales-Llamas DY, El-Ghiaty MA, Braun S, Sahid D, Khan L, Kwan EA, Roth DK, Ferdaoussi M, Fahlman RP, Dyck JRB.   +15 more
europepmc   +1 more source